493 related articles for article (PubMed ID: 17693992)
41. Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response.
Lee SG; Heo DS; Yoon SJ; Jee YS; Kang JO; Kim K; Kim CD; Sung MW; Kim NK
Anticancer Res; 2000; 20(4):2681-6. PubMed ID: 10953343
[TBL] [Abstract][Full Text] [Related]
42. Potentiation of oncolytic adenoviral vector efficacy with gutless vectors encoding GMCSF or TRAIL.
Burroughs KD; Kayda DB; Sakhuja K; Hudson Y; Jakubczak J; Bristol JA; Ennist D; Hallenbeck P; Kaleko M; Connelly S
Cancer Gene Ther; 2004 Feb; 11(2):92-102. PubMed ID: 14730331
[TBL] [Abstract][Full Text] [Related]
43. [Application of fusion gene mGM-CSF/hIL-2 to specific immunotherapy induced by hepatic tumor cell vaccine].
Yang W; Guo C; Liu QG
Ai Zheng; 2008 Feb; 27(2):149-54. PubMed ID: 18279611
[TBL] [Abstract][Full Text] [Related]
44. CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor--armed oncolytic adenovirus for the treatment of bladder cancer.
Ramesh N; Ge Y; Ennist DL; Zhu M; Mina M; Ganesh S; Reddy PS; Yu DC
Clin Cancer Res; 2006 Jan; 12(1):305-13. PubMed ID: 16397056
[TBL] [Abstract][Full Text] [Related]
45. Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide.
Aghi M; Rabkin SD; Martuza RL
Cancer Res; 2007 Jan; 67(2):440-4. PubMed ID: 17234749
[TBL] [Abstract][Full Text] [Related]
46. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV.
Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y
Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286
[TBL] [Abstract][Full Text] [Related]
47. Tumor regression induced by intratumor therapy with a disabled infectious single cycle (DISC) herpes simplex virus (HSV) vector, DISC/HSV/murine granulocyte-macrophage colony-stimulating factor, correlates with antigen-specific adaptive immunity.
Ali SA; Lynam J; McLean CS; Entwisle C; Loudon P; Rojas JM; McArdle SE; Li G; Mian S; Rees RC
J Immunol; 2002 Apr; 168(7):3512-9. PubMed ID: 11907113
[TBL] [Abstract][Full Text] [Related]
48. Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas.
Malhotra S; Kim T; Zager J; Bennett J; Ebright M; D'Angelica M; Fong Y
Surgery; 2007 Apr; 141(4):520-9. PubMed ID: 17383529
[TBL] [Abstract][Full Text] [Related]
49. An Oncolytic Adenovirus Encoding Decorin and Granulocyte Macrophage Colony Stimulating Factor Inhibits Tumor Growth in a Colorectal Tumor Model by Targeting Pro-Tumorigenic Signals and via Immune Activation.
Liu Z; Yang Y; Zhang X; Wang H; Xu W; Wang H; Xiao F; Bai Z; Yao H; Ma X; Jin L; Wu C; Seth P; Zhang Z; Wang L
Hum Gene Ther; 2017 Aug; 28(8):667-680. PubMed ID: 28530155
[TBL] [Abstract][Full Text] [Related]
50. [Enhanced antitumor effect of suicide gene therapy by SCF, GM-CSF gene transfer in vivo and its immunological mechanism].
Huang X; Cao X; Zhang W
Zhonghua Zhong Liu Za Zhi; 1998 Jul; 20(4):270-3. PubMed ID: 10920981
[TBL] [Abstract][Full Text] [Related]
51. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
52. Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer.
Sahin TT; Kasuya H; Nomura N; Shikano T; Yamamura K; Gewen T; Kanzaki A; Fujii T; Sugae T; Imai T; Nomoto S; Takeda S; Sugimoto H; Kikumori T; Kodera Y; Nishiyama Y; Nakao A
Cancer Gene Ther; 2012 Apr; 19(4):229-37. PubMed ID: 22193629
[TBL] [Abstract][Full Text] [Related]
53. Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system.
Fukuhara H; Ino Y; Kuroda T; Martuza RL; Todo T
Cancer Res; 2005 Dec; 65(23):10663-8. PubMed ID: 16322208
[TBL] [Abstract][Full Text] [Related]
54. Development of a rapid method to generate multiple oncolytic HSV vectors and their in vivo evaluation using syngeneic mouse tumor models.
Terada K; Wakimoto H; Tyminski E; Chiocca EA; Saeki Y
Gene Ther; 2006 Apr; 13(8):705-14. PubMed ID: 16421599
[TBL] [Abstract][Full Text] [Related]
55. Effective therapy of metastatic ovarian cancer with an oncolytic herpes simplex virus incorporating two membrane fusion mechanisms.
Nakamori M; Fu X; Meng F; Jin A; Tao L; Bast RC; Zhang X
Clin Cancer Res; 2003 Jul; 9(7):2727-33. PubMed ID: 12855653
[TBL] [Abstract][Full Text] [Related]
56. Intratumoral injection of herpes simplex virus HF10 in recurrent head and neck squamous cell carcinoma.
Fujimoto Y; Mizuno T; Sugiura S; Goshima F; Kohno S; Nakashima T; Nishiyama Y
Acta Otolaryngol; 2006 Oct; 126(10):1115-7. PubMed ID: 16923721
[TBL] [Abstract][Full Text] [Related]
57. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
58. Targeting human glioma cells using HSV-1 amplicon peptide display vector.
Ho IA; Miao L; Sia KC; Wang GY; Hui KM; Lam PY
Gene Ther; 2010 Feb; 17(2):250-60. PubMed ID: 19812609
[TBL] [Abstract][Full Text] [Related]
59. [Expression, purification and identification of mouse granulocyte-macrophage colony-stimulating factor].
Wen Q; Ma L; Su J; Luo W; Wang XN
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Aug; 26(8):1124-7. PubMed ID: 16939899
[TBL] [Abstract][Full Text] [Related]
60. Live cell vaccines expressing B7.1, monocyte chemoattractant protein 1 and granulocyte-macrophage colony stimulation factor derived from mouse HPV16-transformed cells.
Lakatosová-Andelová M; Jinoch P; Dusková M; Marinov I; Vonka V
Int J Oncol; 2008 Jan; 32(1):265-71. PubMed ID: 18097567
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]